Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Minh Bui

Cardiovascular Disease Yuba City, CA Medical Doctor

NPI 1447226824 CMS profile 292264

481 Plumas Blvd, Ste 202, Yuba City, CA 95991

Open in the dashboard

General payments

$6,503

206 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Minh Bui of Yuba City, CA is reported in the CMS Open Payments database as having received $6,503 across 206 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $596 8
2024 General $410 8
2023 General $624 25
2022 General $940 37
2021 General $1,034 44
2020 General $624 26
2019 General $2,275 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Minh Bui
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Minh Bui were reported at $596. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Minh Bui Cardiovascular Disease median Middle half National median
2019 $2,275 $450 $127–$1,392 $163
2020 $624 $242 $77–$751 $114
2021 $1,034 $335 $101–$1,037 $132
2022 $940 $395 $121–$1,211 $149
2023 $624 $443 $136–$1,283 $160
2024 $410 $450 $136–$1,323 $164
2025 $596 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,597 83 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $323 15 payments
  3. Sanofi-Aventis U.S. LLC $293 13 payments
  4. Medtronic, Inc. $288 2 payments
  5. AstraZeneca Pharmaceuticals LP $256 15 payments
  6. Merck Sharp & Dohme Corporation $232 11 payments
  7. Amarin Pharma Inc. $205 13 payments
  8. Janssen Pharmaceuticals, Inc $197 10 payments
  9. Novo Nordisk Inc $188 10 payments
  10. Pfizer Inc. $166 7 payments
  11. Other $759 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,288 199 payments
  2. Travel and Lodging $1,215 7 payments
Products named General payments · program years 2019–2025
  1. Allure CRT Pacemaker $1,275 12 payments
  2. AVEIR $443 6 payments
  3. Merlin Connectivity and Remote $362 9 payments
  4. JARDIANCE $285 12 payments
  5. VERQUVO $219 10 payments
  6. XARELTO $197 10 payments
  7. MULTAQ $190 8 payments
  8. Quadra Allure MP RF CRT Pacemkr $188 2 payments
  9. MERLIN@HOME $180 8 payments
  10. FARXIGA $176 10 payments
  11. Other $3,521 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,160

Median for Cardiology: 2,533

Drug cost

$276,028

Median for Cardiology: $485,213

Branded share of claims

31.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 129 $152,971
Entresto Sacubitril/Valsartan Brand 38 $44,294
Xarelto Rivaroxaban Brand 29 $31,135
Jardiance Empagliflozin Brand 17 $19,677
Brilinta Ticagrelor Brand 19 $11,299
Ranolazine Er Ranolazine Brand 27 $4,561
Metoprolol Succinate Generic 120 $1,704
Propafenone Hcl Generic 18 $1,651
Amiodarone Hcl Generic 55 $912
Nebivolol Hcl Generic 20 $825

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$148,062

Of which drugs: $524

Medicare patients

359

Average age 79

Services billed

2,078

166 women, 193 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 59%
Arthritis 56%
Ischemic heart disease 55%
Diabetes 43%
Heart failure 35%
Chronic kidney disease 35%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 20 80 $459

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

206 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record